Comparison
Office stock vs patient-specific fulfilment
These are two different transactions, not two ways of doing one. Patient-specific fulfilment is a prescription for an identified individual patient, which is what 21 U.S.C. § 353a is written around and which a state-licensed 503A pharmacy can fill. Office stock names no patient, falls outside that exemption, and can only come from a facility registered with FDA as an outsourcing facility under section 503B — and then only where the destination state permits the practice to hold it.
Which one are you actually running?
The test is whether a patient is named before the preparation is made or released.
If a named patient exists, you are running patient-specific fulfilment, whatever the product physically does afterwards and wherever it is delivered. If no patient is named, you are holding stock, whatever it is called on the invoice. Everything else on this page follows from that one fact, which is why getting it wrong at the start propagates into every other answer.
The reason the distinction is load-bearing rather than semantic is that federal law attaches to it. Section 353a exempts a compounded drug from current good manufacturing practice, adequate directions for use and new drug approval where it is "compounded for an identified individual patient based on the receipt of a valid prescription order." Remove the patient and the exemption does not attach.
The comparison
| Patient-specific fulfilment | Office stock | |
|---|---|---|
| Names a patient before release | Yes | No |
| Federal provision it sits under | § 353a, for a state-licensed 503A pharmacy; also available from an outsourcing facility | § 353b only |
| Who can supply it | A state-licensed 503A pharmacy, or a facility registered with FDA as an outsourcing facility under section 503B | Only a facility registered with FDA as an outsourcing facility under section 503B |
| Manufacturing-practice regime of the supplier | Exempted for a 503A pharmacy by § 353a | Current good manufacturing practice applies; § 353b does not exempt it |
| How it is ordered | As a prescription | As a purchase — Georgia's rules direct ordering "in the same manner as ordering products from a wholesale pharmaceutical distributor... and not by using a prescription drug order" |
| Label on arrival | Bears the named patient | Bears no patient name; federal § 353b(a)(10) labelling governs a 503B shipment |
| Can be delivered to the practice | Yes | Yes, where the state permits the practice to hold it |
| Decided by state law | Whether your licence carries prescriptive authority | Whether the practice may hold it at all, plus any permit the site must hold |
| Basis of the dating on the container | A beyond-use date assigned under the compendial chapter the state has adopted | An expiration date which, under current good manufacturing practice, "shall be determined by appropriate stability testing" |
What patient-specific fulfilment is good for, and what it costs you
It is available in every state, because the thing that authorises it is federal.
That is its real advantage and it is a large one: you are not negotiating with a patchwork. Where state rules do touch it, several of them go out of their way to confirm it. Illinois, which prohibits sterile office use, still provides that "a sterile compounded drug may be delivered to the prescribing practitioner's office for administration pursuant to a valid patient-specific prescription."
What it costs you is the shelf. There is nothing to reach for at the moment of care that was not ordered for the person in front of you, which is a genuine operational constraint for practices whose model assumes on-hand supply. It also carries the copy-rule burden at the point of prescribing: where a preparation would otherwise be essentially a copy of a commercially available product, the exception requires that "a prescriber determines and documents" a change producing a significant difference "for an identified individual patient." That determination is the prescriber's, it is documented, and it is per patient — a standing protocol does not supply it.
What office stock is good for, and what it costs you
It is the only route to a stocked cabinet, and it is conditional in two places at once.
FDA describes the federal position plainly: outsourcing facilities "may distribute compounded drugs either pursuant to a patient-specific prescription or in response to an order from a health care provider... that is not for an identified individual patient (e.g., for office stock)." Several state boards route office stock to that pathway explicitly — Georgia's prohibition on non-patient-specific supply for human patients carves out outsourcing facilities by name, and Ohio's guidance names the outsourcing-facility route directly.
The costs are real and worth stating plainly. Section 353b preempts nothing at state level, so the facility needs the destination state's credential as well, and the issuing agency was not consistent across the states we read. Some states close the door entirely: Colorado's rules provide that "nonresident prescription drug outlets shall not distribute compounded products into Colorado," outside a patient-specific or veterinary lane. And the answer can expire — Arizona permits compounded office stock only for veterinarians from 5 September 2026, with human office use prohibited from that date, while leaving its outsourcing-facility licensure layer untouched.
Does delivering to the practice make it office stock?
No, and this is the most common way the two get conflated.
A preparation compounded against a named patient's prescription and then delivered to the practice for administration is that patient's medication sitting in your building. It is not inventory, it cannot be given to a different patient, and it did not become stock by arriving. Illinois expressly excludes that delivery from its own definition of office use — a useful reminder that it is a different transaction rather than a lighter form of the same one.
The practical test is not location. It is whether, at the moment the preparation was released by the pharmacy, a specific person's name was attached to it.
What about compounding ahead of the order?
That is a third thing, and it belongs to patient-specific fulfilment rather than to stock.
Section 353a permits compounding "in limited quantities before the receipt of a valid prescription order" based on a history of the pharmacist receiving valid orders within an established relationship between prescriber, patient and pharmacist. The stock exists before the order does — but it is still released against a patient-specific order when one arrives. Georgia's rule permits anticipatory preparation and provides that such stock shall not be dispensed until a valid patient-specific order is received; North Carolina carries the identical limb.
So anticipatory compounding is a pharmacy's inventory practice, not a permission for your practice to hold unassigned product.
What does each require of your practice?
Patient-specific fulfilment requires prescriptive authority. Office stock can require a permit belonging to the site.
That second requirement is the one most often missed, because it attaches to the address rather than to the prescriber. Ohio treats a prescriber practice holding dangerous drugs as needing a terminal distributor licence, while naming possession of compounded preparations supplied by an Ohio-licensed outsourcing facility as a lower-risk activity that does not itself trigger licensure — and adding that "preparation of such medications in advance of administration requires licensure." Florida requires a health care clinic establishment permit where a business entity purchases prescription drugs, with a carve-out for purchases by a licensed practitioner under their own licence.
Records diverge too. Several states impose an inventory-and-retention duty on a practice that holds stock and none on a practice that does not, and most of those duties bind the practice regardless of which pathway supplied the product.
Does a state permission settle it?
Only if the state rule does not condition itself on federal law — and several of them do.
North Carolina's office-use rule permits a pharmacy to supply compounded drug products to prescribers, then adds that such compounding "shall comply with applicable federal law." New Jersey bars the practice for human use "except to the extent permitted by Federal law." A rule phrased that way has not created a federal safe harbour; it has handed the question back to section 353a, which conditions on the identified individual patient.
When a supplier cites a state rule containing that phrase, the rule text is half the citation. The other half is which federal provision they say is satisfied, and how.
How this comparison was made
From the statutory text and from the state rules we read in full, in that order.
The federal layer is quoted from 21 U.S.C. §§ 353a and 353b and from FDA's own published description of the two sections. The state examples are quoted from the rules of the states read in full from primary sources — Georgia, North Carolina, Ohio, Louisiana, New Jersey, Illinois, Texas, Florida, California, New York, Arizona and Colorado. Where a state is not named, we have not read it, and we do not infer its position from a neighbour's.
No pharmacy or outsourcing facility is named, assessed or ranked here, and no supplier's compliance status is asserted. The comparison is between two transaction types; the choice between them is made by your state and by the shape of your order, not by a preference.
All statements on this page are as of 29 August 2026, except Arizona's incoming rule, which is stated with its own effective date of 5 September 2026.
Where to go from here
Whether your state permits your practice to hold stock is answered, with each state's rule text and citation, at office-use compounding by state. The two pathways themselves are set out at 503A pharmacies and 503B outsourcing facilities compared, and the workflow either transaction runs through is at how clinics order compounded medications. If the preparation you have in mind resembles an available product, the boundary that governs it is at compounded and commercially available compared.
To have your state, your practice type and your intended preparations sorted into one of these two transactions before you commit to either, you can apply for an account.